[go: up one dir, main page]

CA2230690A1 - Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments - Google Patents

Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments

Info

Publication number
CA2230690A1
CA2230690A1 CA002230690A CA2230690A CA2230690A1 CA 2230690 A1 CA2230690 A1 CA 2230690A1 CA 002230690 A CA002230690 A CA 002230690A CA 2230690 A CA2230690 A CA 2230690A CA 2230690 A1 CA2230690 A1 CA 2230690A1
Authority
CA
Canada
Prior art keywords
pain
administration
ketamine
transmucosal
management
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002230690A
Other languages
English (en)
Other versions
CA2230690C (fr
Inventor
Stuart L. Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2230690A1 publication Critical patent/CA2230690A1/fr
Application granted granted Critical
Publication of CA2230690C publication Critical patent/CA2230690C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002230690A 1995-08-30 1996-08-29 Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments Expired - Fee Related CA2230690C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US294695P 1995-08-30 1995-08-30
US60/002,946 1995-08-30
PCT/US1996/014095 WO1997007750A1 (fr) 1995-08-30 1996-08-29 Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments

Publications (2)

Publication Number Publication Date
CA2230690A1 true CA2230690A1 (fr) 1997-03-06
CA2230690C CA2230690C (fr) 2008-12-23

Family

ID=21703322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002230690A Expired - Fee Related CA2230690C (fr) 1995-08-30 1996-08-29 Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments

Country Status (3)

Country Link
JP (2) JPH11511466A (fr)
CA (1) CA2230690C (fr)
WO (1) WO1997007750A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103256A1 (fr) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
WO2003004031A1 (fr) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Administration parenterale de 6-hydroxy-oxymorphone destinee a etre utilisee en tant qu'analgesique
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DE60223254T2 (de) 2001-07-06 2008-08-14 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
JP2006510618A (ja) * 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
WO2004087209A1 (fr) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. Preparation pour assurer une concentration sanguine therapeutiquement efficace d'un potentialisateur d'activite analgesique
EP2766339B1 (fr) 2011-10-14 2021-06-09 The United States Of America, as represented by the Secretary, Department of Health & Human Services Utilisation de la (2r, 6r)-hydroxynorkétamine et d'autres métabolites hydroxylés stéréo-isomères de la (r,s)-kétamine dans le traitement de la dépression et de la douleur neuropathique
US20140079740A1 (en) * 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
WO2014152196A1 (fr) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Composition pharmaceutique d'hydrochlorure de s-kétamine
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US11191734B2 (en) * 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US9963435B2 (en) 2016-08-31 2018-05-08 Dart Neuroscience, Llc Compounds for therapeutic use
CN111278807B (zh) 2017-08-17 2022-07-22 凯瑞康宁生物工程（武汉）有限公司 活性氧清除剂衍生物的制备及用途
CN111356699B (zh) 2017-09-04 2022-08-23 凯瑞康宁生物工程（武汉）有限公司 活性氧清除剂的制备及用途
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CA3086478A1 (fr) 2017-12-22 2019-06-27 Janssen Pharmaceuticals, Inc. Esketamine pour le traitement de la depression
CN111836798B (zh) * 2018-01-10 2022-04-15 凯瑞康宁生物工程（武汉）有限公司 氯胺酮的前药、其组合物和用途
IL318198A (en) 2019-03-05 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
WO2020232274A1 (fr) * 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Formulation de kétamine pour injection sous-cutanée
TW202139981A (zh) 2020-01-22 2021-11-01 美商西羅斯醫療公司 降低nmda拮抗劑之副作用
TWI844074B (zh) 2021-08-13 2024-06-01 凱瑞康寧生技股份有限公司 氯胺酮衍生物之醫藥組成物及口服劑型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
CA2115792C (fr) * 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain

Also Published As

Publication number Publication date
WO1997007750A1 (fr) 1997-03-06
JPH11511466A (ja) 1999-10-05
JP2009073842A (ja) 2009-04-09
CA2230690C (fr) 2008-12-23

Similar Documents

Publication Publication Date Title
CA2230690A1 (fr) Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments
CA2184077A1 (fr) Administration nasale et oculaire de ketamine pour le traitement de la douleur et les desintoxications
EP1555025A3 (fr) Utilisation d'analogues de déhydroépiandrostérone pour le traitement de l'asthme
CA2223776A1 (fr) Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens
NZ336055A (en) An oral sustained release formulation of opioids
CZ176495A3 (en) The use of riluzol for preparing a medicament suitable for treating parkinson's disease and parkinson's syndromes
AU685075B2 (en) Pharmaceutical composition for treating nicotine dependence
WO2003092617A3 (fr) Combinaisons destinees au traitement de troubles cutanes inflammatoires
MXPA04003548A (es) Tratamiento de neumonia severa mediante administracion de inhibidor de via factor de tejido.
RO116771B1 (ro) Metodă pentru prevenirea sau tratamentul dependenţei, toleranţei sau abuzului de benzodiazepine
WO2004050025A3 (fr) Methode de traitement de la douleur aigue au moyen d'une forme posologique unitaire contenant de l'ibuprofene et de l'oxycodone
HUT68171A (en) Preparations containing 4-aminopyridine for the treatment of neurological conditions
CA2403994A1 (fr) Administration nasale d'agents pour traiter la gastroparesie
Zachariae et al. Ciclosporin A in acrodermatitis continua
CA2150183A1 (fr) Composition pharmaceutique pour le traitement des affections hemoroidales
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
US4355044A (en) D-Phenylalanine treatment
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
Epstein Rantidine and confusion.
AU7639796A (en) Novel drug for relieving pain and promoting the removal of calculi in urolithiasis
WO2002089848A3 (fr) Methode de traitement du diabete
WO2000006696A3 (fr) Procede de modulation du fonctionnement de facteurs de transcription
WO2001000191A3 (fr) Utilisation de fosphenytoine pour le traitement de douleur neuropathique aigue
CA2237643A1 (fr) Agent therapeutique contre l'insuffisance hepatique aigue

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140829